The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The problem and the reason for lack of movement with OPTI other than a drain down has is that it consists of mainly shareholders that reside on adfn who have sank half their house in OPTI and so are basically sitting on the investment until they hope their moment comes. Because of this OPTI may not always provide the fireworks of say other promiscuous AIM shares so given this you have to just believe in the company and the momentum its building, or sell up if it's not frisky enough.
I had 75p down to buy James otherwise you end up averaging down at the wrong price. So looks like they released the rns to say a commercial agreement is coming so that is very positive rather than distribution agreements which are a bit open ended.
Doh! This is right link: https://walbrookpr.sharepoint.com/clientsites/OPTI/Shared%20Documents/Logo/OptiBiotix-logo-450-dpi.jpg
That's impressive I have 'only' 55,000 at present and it is part of a retirement plan that I would like to effect within my lifetime so I have a reasonable tie with this share. I will also average down should the share price dip below 75p and increase my holdings further.
Good luck to you and everyone, I want OPTI to do well but boy was opti over hyped and I'm tired of the yo-yo shareprice, whatever the company can do to steady this ship I'm sure we'd all appreciate but with TW put a 125p price on this coupled with the head banging yoyo shareprice will basically **** off PIs and 125p will be a hard ceiling to break. Some very good news will need to be released to provide the necessary momentum.
And by banned I have not been banned, the adfn thread leaders choose to exclude who they like. They chose to exclude me and keep their positivity rose tints on. So no I have not been banned per say so just wanted to explain that. It's basically adfn model to encourage people to subscribe.